Hycells Launches a Groundbreaking Product | γδ T (Vγ9Vδ2-T) Cell Expansion Kit
Release Date:
2023-08-16 13:29
Introduction to γδ T Cells
γδ T cells represent an emerging frontier in tumor immunology; like αβ T cells, they can exert cytotoxic effector functions (ADCC) and produce pro-inflammatory cytokines. The key distinction is that γδ T cells recognize tumor antigens in an MHC-unrestricted manner, endowing them with the characteristics of a universal cell therapy product. The TCRγδ on the surface of γδ T cells does not require binding to MHC molecules or antigen presentation by antigen-presenting cells (APCs); instead, it can directly recognize and bind antigenic molecules. However, the repertoire of TCRγδ receptors is relatively limited and lacks diversity, resulting in a narrower antigen recognition spectrum for γδ T cells. γδ T cells in different tissues express distinct TCRγδ variants and recognize antigens with varying properties, whereas γδ T cells within the same tissue typically express the same TCRγδ variant and recognize antigens of a similar nature.
To date, no serious adverse reactions associated with γδ T-cell therapy have been reported. This therapeutic approach has demonstrated robust efficacy in both hematologic malignancies and solid tumors, independent of specific MHC expression. By sensing stress signals uniquely expressed by cancer cells while sparing healthy cells, γδ T-cell therapy exhibits minimal toxicity and virtually no side effects, thereby holding great promise for broader clinical applications.
The use of clinically established, highly efficient, and safe in vitro expansion methods to generate standard γδ T cells has become an essential step in the treatment of malignant tumors; consequently, the development of an effective and safe in vitro γδ T-cell expansion system represents a pressing challenge that urgently needs to be addressed.
Provided by Hycells Biotechnology
γδ T Cell Samples & Expansion Kit
Hycells Bio offers γδ T-cell donor pre-screening services, in conjunction with the company’s proprietary HiXpan product. TM The γδT cell expansion kit is used to activate and proliferate γδT cells.
HiXpan TM γδ T Cell Expansion Kit
for the culture and expansion of human γδT cells
Robust expansion of γδT cells with high yield and frequency
Feeder- and serum-free culture conditions
Expanded γδ T cells are functional with cytotoxic potential.
HiXpan TM γδ T Cell Expansion Kit [Operating Procedure]
HiXpan TM γδ T Cell Expansion Kit
for the culture and expansion of human γδT cells
Single-donor blood may be used as the starting sample;
Alternatively, cryopreserved PBMCs may be used as the starting sample;
On days 3–5, retroviral transduction is recommended.
Maintain the optimal cell density during the expansion phase at 1 × 10 6 cells/mL;
Optimal γδ T cells with superior phenotypic and functional characteristics can be harvested on days D18–D22.
The infusion dose range is 1–20 × 10. 7 cells/kg.
HiXpan TM γδ T Cell Expansion Case
Three healthy donors (H01, H02, H03):
for the culture and expansion of human γδT cells
Frozen PBMCs were used as the starting material;
Amplified 250-fold;
D14 purity > 90%;
Cytotoxicity of γδ T cells
Statistics: Proportion Distribution of γδ T Cells from Healthy Donors (15 Cases)
Note: The initial positive rate of γδ T cells is not correlated with the proportion of expanded γδ T cells; however, a higher initial proportion of γδ T cells is associated with a higher success rate of expansion.
Initial γδ T cell ratio
Proportion of activated γδ T cells (Day 7)
HiXpan TM Phenotypic Analysis of γδ T Cells (Day 10)
Note: γδ T cells exhibit high expression of molecules such as HLA-DR, CD56, and NKG2D, suggesting that they may possess NK-like antitumor cytotoxic activity.
HiXpan TM gamma delta T Cell Phenotype Analysis
Related News
(II) Security Assurance Section | Safety First, Defense Prioritized
Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.
This article will examine how He Yousheng proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.
In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.
Recently, the research team led by Researcher Bian Yingjie at the Guangzhou National Laboratory, in collaboration with partners from Sun Yat-sen University, published a study titled “Iron overload in the tumor microenvironment induces CD8⁺ T cell ferroptosis and dysfunction” in the internationally renowned academic journal Nature Communications.
Hycells Recruitment | Never Stop Exploring, Never Stop Innovating
The company consistently upholds its core values of “people‑centricity, quality first, and innovation as the foundation,” remains driven by technological innovation, and sets new industry benchmarks for domestic innovation, thereby laying a solid foundation for the development and global advancement of China’s innovative pharmaceutical sector.
The HiXpan® NK Serum-Free Culture Kit, Version 3.0, is manufactured in strict compliance with GMP standards, and its production system fully adheres to relevant guidelines and regulations, including the “818 Requirements,” positioning it for pharmaceutical‑grade manufacturing and applications.
Contact Us
Phone: 021-36696819
Mobile phone:13061948224(Ms. Yu)
Email:monika@hys-bio.com
Wuxi Headquarters: 4th Floor, No. 15-1, Xianfeng Middle Road, Anzhen Subdistrict, Xishan District, Wuxi City
Shanghai Branch: Room 503, Building 2, No. 999 Jiangyue Road, Minhang District, Shanghai
Official Website
WeChat Official Account
Message Board